Member Info for EarlyBird-Rns

Selling on the rise... But it was not possible... Even put in a 'At Best' order for nearly 5 minutes, but did not execute! Was in profit massively, but ending up losing a few quid once I was able to sell! Can't win them all!

Tough selling...

Never do:)

Loving it!!!!

She's flying!

Funds to LED has been made in full and final settlement of all of the Investors's legal obligations under the original subscription agreements. The Placing Shares are being issued at a price of 75 pence per share representing a premium of 780 per cent. to the closing mid-price on 10 July 2014.

Check it out!

11 July 2014 LED International Holdings Limited ("LED" or the "Company") Fund raise update and issue of new ordinary shares The board of LED (the "Board") is pleased to provide an update to shareholders following its announcements on 26 February 2014 and on 26 June 2014. The Company, Speedy Dragon Holdings Limited and Rubyfield Holdings Limited (the "Investors") have reached a supplementary agreement in relation to the placing of 3,875,000 new ordinary shares (the "Placing Shares") and the conversion of the working capital loan, further details of which are set out in LED's announcement on 30 December 2013. LED, via its wholly owned subsidiary, Shenzhen Green Pearl Energy Management Services Company Limited, is now in receipt of subscription funds of RMB25,000,000 million (approximately GBP2.35 million) (the "Subscription Funds") from the Investors. Under the terms of the supplemental placing agreement, payment of the Subscription Funds to LED has been made in full and final settlement of all of the Investors's legal obligations under the original subscription agreements. The Placing Shares are being issued at a price of 75 pence per share representing a premium of 780 per cent. to the closing mid-price on 10 July 2014. LED will use the proceeds of the Subscription Funds for general working capital purposes. Further updates in relation to the issue of convertible loan notes and placing announced on 31 March 2014 will be made at the appropriate time. In addition, LED has also issued 1 ordinary share which has arisen as a fractional entitlement following LED!|s recent capital reorganisation (the "Reorganisation Share"). An application will be made for the Placing Shares and the Reorganisation Share to be admitted to trading on AIM and it is expected that dealings will commence on 17 July 2014. Following the issue of the Placing Shares and the Reorganisation Share, the Company's issued share capital will be 8,907,935 ordinary shares. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company. Following the issue of the Placing Shares, the Investors will be interested, in aggregate, in 43.5% of the enlarged issued share capital of LED. The Placing Shares have been issued to the Investors in equal tranches. For further information: LED International Holdings Limited Stephen Chan - Chief Executive Officer +852 2243 3100

11 July 2014 Haydale Graphene Industries plc ("Haydale" or the "Company") Announces Collaboration Agreement with Swansea University's Welsh Centre for Printing and Coatings ("WCPC") Haydale Graphene Industries plc (AIM:HAYD), the Company focused on enabling technology for the commercialisation of graphene, is pleased to announce that it has signed a research and collaboration agreement with the WCPC, one of the world's leading R&D centres for printing and coating processes, based at Swansea University. The WCPC will develop and refine commercial ink formulations supplied by Haydale to meet the growing interest in graphene based inks and coatings. The collaboration is also investigating the exploitation of functionalised graphene and other carbon nano-materials developed by Haydale in areas such as transparent conductive films, barrier coatings and 3D printing. Professor Tim Claypole, College of Engineering Swansea University and Director of WCPC, will lead the WCPC programme. Commenting, Haydale Chief Executive, Ray Gibbs said: "Working with the WCPC is a key element of our focus on inks and coatings and is a great fit for us. Having access to a wide range of nano materials and then using our unique functionalisation process means we can provide the most appropriate material for the WCPC to use. In turn, the resources and capability at the WCPC mean we can move quickly on product development. We have already successfully produced a consistent quality conductive ink that we are now starting to market. This collaboration is all about taking the next step towards the commercial uptake of our inks by demonstrating that we can successfully functionalise the right material to meet specific manufacturing needs." Prof Tim Claypole, founder and director of the WCPC, Swansea University, added "this is a good example of where the expertise and facilities of the WCPC, which have been developed with the support of the Welsh Government Academic Expertise for Business (A4B) programme, are being used to help a help a leading edge Welsh company grow its highly innovative product portfolio." "A crucial part of this project is the development of standard operating procedures for the manufacturing process that will ensure a highly consistent, quality product. These will form the basis for any future scale up to commercial production. This understanding of the manufacturing tolerances for critical parameters will also be fed into International Standards." "The WCPC will further benefit from this project as it will have an improved understanding of the operating and quality assurance procedures. This it will be able to apply to the research into the creation of inks and coatings based on other novel materials"

Out!

10 July 2014 Plaza Centers N.V. (the "Company" or "Plaza") DUTCH COURT APPROVES DEBT RESTRUCTURING PLAN Plaza announces that today, following the confirmation hearing held on 8 July 2014, the Dutch Court has confirmed the Dutch restructuring plan (the "Plan"). This follows the Company receiving approval from 92% of creditors voting in favour of the Plan. As previously announced, approval of the Plan defers the principal maturities of the Company's Series A and Series B bonds for at least 3.5 years and provides bondholders with significantly improved terms, including additional interest of 1.5% p.a; 13.21% of the shares in the Company post its proposed EUR 20 million rights issuance; certain covenants on operations; and an option for early repayments when any assets may be sold. The Plan together with a prospectus detailing the proposed amendments to the terms of the Israeli Series A and Series B bonds, as well as other provisions applicable to the relevant creditors, is available to view on the Company's website at: www.plazacenters.com. For further details, please contact: Plaza Ran Shtarkman, President and CEO +36 1 462 7221 Roy Linden, CFO +36 1 462 7222 FTI Consulting Stephanie Highett / Nina Legge +44 20 3727 1000 Notes to Editors Plaza Centers N.V. (www.plazacenters.com) is a leading emerging markets developer of shopping and entertainment centres with operations in Central and Eastern Europe and India. It focuses on constructing new centres and, where there is significant redevelopment potential, redeveloping existing centres in both capital cities and important regional centres. The Company is dual listed on the Main Board of the London Stock Exchange and, as of 19 October 2007, the Warsaw Stock Exchange (LSE:"PLAZ", WSE: "PLZ/PLAZACNTR"). Plaza Centers N.V. is an indirect subsidiary of Elbit Imaging Ltd. ("EI"), an Israeli public company whose shares are traded on both the Tel Aviv Stock Exchange in Israel and the NASDAQ Global Market in the United States. It has been active in real estate development in emerging markets for over 18 years. This information is provided by RNS The company news service from the London Stock Exchange END

Will have a look:) ABZA is sort of similar and reminds me of GWIN first day of trading last year... Made a bloody fortune in a few days day... Bought a few tranches between 10p - 13 and sold between 20p-23p... Nick... Do you think MIO will resume trading today? Once again, thanks for the heads-up yesterday... Made a few $$$...

The next jump in the order books is 88p... There is not any depth in the books and she could really fly!

Waiting for a few buys to be executed then I'm in... Keep hitting the refresh button:)

Getting quoted 84.80p...

There are so few shares on offer... She could really climb with a little attention!

Morning... I think I'm going to give her a go!

Could really move on little volume... A relatively small market cap and very few shares on offer... And it appears the company is actually making $$$! Certainly may be worth a punt!

FIRST DAY OF DEALINGS ON AIM 10 July 2014 London, UK - Abzena plc ("Abzena", the "Group" or the "Company"), a revenue-generating life sciences company providing services and technologies that enable the development of better biopharmaceutical products, is pleased to announce the Admission of its ordinary shares to trading on the AIM market of the London Stock Exchange; trading of these shares will commence at 8.00am today under the ticker "ABZA" (ISIN number GB00BN65QN46). In conjunction with its Admission to AIM, Abzena raised GBP20 million (before expenses) by way of a placing of 25,000,000 new ordinary shares at 80 pence per share (the "Placing Price"). 3,398,750 existing ordinary shares were also sold at the Placing Price. Cenkos Securities plc is acting as nominated adviser and broker to the Company. John Burt, CEO of Abzena said: "We are delighted to have completed our IPO. We are confident that the business we have created for enabling our customers and partners to develop better biopharmaceuticals will thrive as pharmaceutical companies increasingly seek external expertise to advance their programmes. We believe that Abzena is well positioned to capitalise on this demand and we're excited about the opportunity to grow and develop the business, and to deliver value to all our stakeholders." Admission Statistics Placing Price 80 pence per share Number of Existing Ordinary Shares in issue on Admission immediately prior to issue of New Ordinary Shares* 72,428,858 Number of New Ordinary Shares being issued pursuant to the Placing 25,000,000 Number of Vendor Ordinary Shares being sold pursuant to the Placing 3,398,750 Number of Ordinary Shares in issue immediately following Admission 97,428,858 Percentage of Enlarged Share Capital represented 25.7 per cent. by the New Ordinary Shares issued pursuant to the Placing Market capitalisation of the Company at the Placing GBP77,943,086 Price immediately following Admission GBP20,000,000 Gross proceeds of the Placing receivable by the Company Estimated net proceeds of the Placing receivable GBP18,570,000 by the Company Gross proceeds of the Placing receivable by the GBP2,719,000 Vendors * Includes the Option Exercise Shares and Warrant Exercise Shares For more information, please contact: John Burt (Chief Executive Officer; john.burt@abzena.com) Julian Smith (Chief Financial Officer; julian.smith@abzena.com) Abzena plc Tel: +44 (0)1223 903351 Christopher Golden and Bobbie Hilliam, C

ft.com > companies > technology > Science Search Sign in Subscribe Home UK World Companies Energy Financials Health Industrials Luxury 360 Media Retail & Consumer Tech Telecoms Transport By Region Tools Markets Global Economy Lex Comment Management Personal Finance Life & Arts July 8, 2014 12:10 am Simple test for Alzheimer’s draws closer By Clive Cookson, Science Editor A simple test for early Alzheimer’s disease has come a step closer, as UK scientists announce that certain proteins in blood can predict the onset of dementia in people suffering from mild cognitive impairment. A partnership between King’s College London and Proteome Sciences, a UK biotechnology company, developed the potential blood test during a 10-year programme funded partly by the charity Alzheimer’s Research UK. The results are published in the journal Alzheimer’s & Dementia. More ON THIS STORY Elderly care rejuvenated in Cornwall World’s biggest dementia study launched Longer lives mean more diseases of old age and rising costs ON THIS TOPIC Urgent action called for on antibiotics Drug groups welcome UK superbug battle PM leads fight against antibiotic resistance Depression still has stigma IN SCIENCE Equistone taps outsourced science market Allied Minds valued at £398m in IPO Musk plans reusable space rockets Venture pursues pig organs for humans “There are thousands of proteins in the blood, and this study is the culmination of many years’ work identifying which ones are clinically relevant,” said Abdul Hye of King’s, lead author. “We now have a set of 10 proteins that can predict whether someone with early symptoms of memory loss, or mild cognitive impairment, will develop Alzheimer’s disease within a year, with a high level of accuracy.” The researchers analysed samples from 1,148 people, of whom 476 already had Alzheimer’s, 220 had mild cognitive impairment and 452 were elderly controls with no symptoms. Their blood was analysed for 26 proteins already shown to be associated with Alzheimer’s. A series of tests, including scans to detect brain shrinkage, then narrowed these down to 10 molecules which predicted with 87 per cent accuracy whether someone with mild impairment would develop Alzheimer’s within a year. “This research does not mean that a blood test for dementia is just around the corner,” cautioned James Pickett, head of research at the Alzheimer’s Society. “Accuracy would need to be improved before it could be a useful diagnostic test.” The next step will be to validate the 10-protein test and reduce the risk of misdiagnosis, with much more extensive clinical testing over the next two or three years. Although the long-term aim is to produce a simple blood test accurate enough for doctors to use in everyday practice, for patients suffering from early memory loss who